{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:43:31Z","timestamp":1791855811781,"version":"4.3.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:00:00Z","timestamp":1571788800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:00:00Z","timestamp":1571788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The purpose of this study was to determine efficacy and safety of cyclosporine A (CsA) for patients with steroid-resistant nephrotic syndrome (SRNS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The Cochrane Library and PubMed were searched to extract the associated studies on Oct 10, 2018, and the meta-analysis method was used to pool and analyze the applicable investigations included in this study. The P(opulation) I(ntervention) C(omparison) O(utcome) of the study were defined as follows: P: Patients with SRNS; I: treated with CsA, cyclophosphamide (CYC), tacrolimus (TAC) or placebo\/not treatment (P\/NT); C: CsA vs. placebo\/nontreatment (P\/NT), CsA vs. CYC, CsA vs. TAC; O: complete remission (CR), total remission (TR; complete or partial remission (PR)), urine erythrocyte number, proteinuria levels, albumin, proteinuria, serum creatinine, and plasma cholesterol, etc. Data were extracted and pooled using RevMan 5.3.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the therapeutic regimen of CsA vs. placebo\/nontreatment (P\/NT), the results indicated that the CsA group had high values of CR, TR, and low values of proteinuria, serum creatinine, and plasma cholesterol when compared with those in the placebo group. In comparing CsA vs. cyclophosphamide (CYC), the results indicated that the CsA group had higher TR than the CYC group. In comparing CsA vs. tacrolimus (TAC), the results revealed insignificant differences in CR, and TR between the CsA and TAC groups. The safety of CsA was also assessed. The incidence of gum hyperplasia in CsA group was higher than that in the P\/NT group, with no differences in incidence of infections or hypertension between CsA and P\/NT groups. There was no difference in the incidence of hypertension between the CsA and TAC groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>CsA is an effective and safe agent in the therapy of patients with SRNS.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12882-019-1575-8","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T17:03:41Z","timestamp":1571850221000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and safety of cyclosporine a for patients with steroid-resistant nephrotic syndrome: a meta-analysis"],"prefix":"10.1186","volume":"20","author":[{"given":"Hong-Yan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xialan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianbiao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqing","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhen","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,23]]},"reference":[{"issue":"6","key":"1575_CR1","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.ekir.2018.07.017","volume":"3","author":"K Asharam","year":"2018","unstructured":"Asharam K, Bhimma R, David VA, Coovadia HM, Qulu WP, Naicker T, et al. NPHS2 V260E is a frequent cause of steroid-resistant Nephrotic syndrome in black south African children. Kidney Int Rep. 2018;3(6):1354\u201362.","journal-title":"Kidney Int Rep"},{"key":"1575_CR2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3389\/fped.2018.00307","volume":"6","author":"JD Varner","year":"2018","unstructured":"Varner JD, Chryst-Stangl M, Esezobor CI, Solarin A, Wu G, Lane B, et al. Genetic testing for steroid-resistant-Nephrotic syndrome in an outbred population. Front Pediatr. 2018;6:307.","journal-title":"Front Pediatr"},{"issue":"6","key":"1575_CR3","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s00467-016-3459-5","volume":"32","author":"S Dogra","year":"2017","unstructured":"Dogra S, Kaskel F. Steroid-resistant nephrotic syndrome: a persistent challenge for pediatric nephrology. Pediatr Nephrol. 2017;32(6):965\u201374.","journal-title":"Pediatr Nephrol"},{"issue":"12","key":"1575_CR4","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1007\/s00467-018-3970-y","volume":"33","author":"U Querfeld","year":"2018","unstructured":"Querfeld U, Weber LT. Mycophenolate mofetil for sustained remission in nephrotic syndrome. Pediatr Nephrol. 2018;33(12):2253\u201365.","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"1575_CR5","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s00467-013-2509-5","volume":"28","author":"OM Akchurin","year":"2013","unstructured":"Akchurin OM, Kaskel FJ. Late steroid resistance in childhood nephrotic syndrome: do we now know more than 40 years ago? Pediatr Nephrol. 2013;28(8):1157\u201360.","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"1575_CR6","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s12882-018-1099-7","volume":"19","author":"T Horinouchi","year":"2018","unstructured":"Horinouchi T, Sako M, Nakanishi K, Ishikura K, Ito S, Nakamura H, et al. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07). BMC Nephrol. 2018;19(1):302.","journal-title":"BMC Nephrol"},{"issue":"12","key":"1575_CR7","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/S2352-4642(18)30283-9","volume":"2","author":"K Tullus","year":"2018","unstructured":"Tullus K, Webb H, Bagga A. Management of steroid-resistant nephrotic syndrome in children and adolescents. Lancet Child Adolesc Health. 2018;2(12):880\u201390.","journal-title":"Lancet Child Adolesc Health"},{"issue":"1","key":"1575_CR8","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12881-018-0714-6","volume":"19","author":"A Siji","year":"2018","unstructured":"Siji A, Karthik KN, Pardeshi VC, Hari PS, Vasudevan A. Targeted gene panel for genetic testing of south Indian children with steroid resistant nephrotic syndrome. BMC Med Genet. 2018;19(1):200.","journal-title":"BMC Med Genet"},{"key":"1575_CR9","doi-asserted-by":"crossref","unstructured":"Liu C, Zhu P, Fujino M, Isaka Y, Ito H, Takahashi K, et al. 5-aminolaevulinic acid (ALA), enhances heme oxygenase (HO)-1 expression and attenuates tubulointerstitial fibrosis and renal apoptosis in chronic cyclosporine nephropathy. Biochem Biophys Res Commun. 2019;508(2):583-9.","DOI":"10.1016\/j.bbrc.2018.11.175"},{"issue":"1","key":"1575_CR10","doi-asserted-by":"publisher","first-page":"16678","DOI":"10.1038\/s41598-018-34891-w","volume":"8","author":"J Groenendyk","year":"2018","unstructured":"Groenendyk J, Paskevicius T, Urra H, Viricel C, Wang K, Barakat K, et al. Cyclosporine a binding to COX-2 reveals a novel signaling pathway that activates the IRE1alpha unfolded protein response sensor. Sci Rep. 2018;8(1):16678.","journal-title":"Sci Rep"},{"issue":"11","key":"1575_CR11","doi-asserted-by":"publisher","first-page":"4506","DOI":"10.1177\/0300060518782017","volume":"46","author":"Y Liu","year":"2018","unstructured":"Liu Y, Yang R, Yang C, Dong S, Zhu Y, Zhao M, et al. Cyclophosphamide versus cyclosporine a therapy in steroid-resistant nephrotic syndrome: a retrospective study with a mean 5-year follow-up. J Int Med Res. 2018;46(11):4506\u201317.","journal-title":"J Int Med Res"},{"issue":"5","key":"1575_CR12","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1093\/ndt\/gfr572","volume":"27","author":"J Gellermann","year":"2012","unstructured":"Gellermann J, Ehrich JH, Querfeld U. Sequential maintenance therapy with cyclosporin a and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome. Nephrol Dial Transplant. 2012;27(5):1970\u20138.","journal-title":"Nephrol Dial Transplant"},{"key":"1575_CR13","unstructured":"Loboda A, Mucha O, Podkalicka P, Sobczak M, Miksza-Cybulska A, Kaczara P, et al. Kidney injury by cyclosporine a is aggravated in heme oxygenase-1 deficient mice and involves regulation of microRNAs. Acta Biochim Pol. 2018;65(4):613-20."},{"issue":"12","key":"1575_CR14","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1007\/s00467-014-2913-5","volume":"29","author":"J Gellermann","year":"2014","unstructured":"Gellermann J, Schaefer F, Querfeld U. Serum suPAR levels are modulated by immunosuppressive therapy of minimal change nephrotic syndrome. Pediatr Nephrol. 2014;29(12):2411\u20134.","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"1575_CR15","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s11596-015-1480-8","volume":"35","author":"ZQ Li","year":"2015","unstructured":"Li ZQ, Hu ML, Zhang C, Wang YM. Efficacy and safety of tacrolimus vs. cyclophosphamide for idiopathic membranous nephropathy: a meta-analysis of Chinese adults. J Huazhong Univ Sci Technolog Med Sci. 2015;35(5):623\u20138.","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"issue":"5","key":"1575_CR16","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1053\/j.ajkd.2008.11.033","volume":"53","author":"S Choudhry","year":"2009","unstructured":"Choudhry S, Bagga A, Hari P, Sharma S, Kalaivani M, Dinda A. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. Am J Kidney Dis. 2009;53(5):760\u20139.","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"1575_CR17","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1001\/archpedi.1988.02150090083029","volume":"142","author":"EH Garin","year":"1988","unstructured":"Garin EH, Orak JK, Hiott KL, Sutherland SE. Cyclosporine therapy for steroid-resistant nephrotic syndrome. A controlled study. Am J Dis Child. 1988;142(9):985\u20138.","journal-title":"Am J Dis Child"},{"issue":"9","key":"1575_CR18","first-page":"651","volume":"56","author":"HY Geng","year":"2018","unstructured":"Geng HY, Ji LN, Chen CY, Tu J, Li HR, Bao R, et al. Mycophenolate mofetil versus cyclosporine a in children with primary refractory nephrotic syndrome. Chin J Pediatr. 2018;56(9):651\u20136.","journal-title":"Chin J Pediatr"},{"issue":"1","key":"1575_CR19","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1681\/ASN.V7156","volume":"7","author":"KV Lieberman","year":"1996","unstructured":"Lieberman KV, Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol. 1996;7(1):56\u201363.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"1575_CR20","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s00467-008-0794-1","volume":"23","author":"C Plank","year":"2008","unstructured":"Plank C, Kalb V, Hinkes B, Hildebrandt F, Gefeller O, Rascher W. Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome-a randomized controlled multicentre trial by the Arbeitsgemeinschaft fur Padiatrische Nephrologie. Pediatr Nephrol. 2008;23(9):1483\u201393.","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"1575_CR21","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1038\/ki.1993.194","volume":"43","author":"C Ponticelli","year":"1993","unstructured":"Ponticelli C, Rizzoni G, Edefonti A, Altieri P, Rivolta E, Rinaldi S, et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int. 1993;43(6):1377\u201384.","journal-title":"Kidney Int"},{"key":"1575_CR22","first-page":"1804","volume":"25","author":"S Valverde","year":"2010","unstructured":"Valverde S, Hernandez A, Velasquez L, Romero B, Mendoza A, Ramon G, et al. Efficacy of prednisone-tacrolimus vs. prednisone - Cyclosporine in steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2010;25:1804.","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"1575_CR23","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1007\/s10157-017-1484-8","volume":"22","author":"X Jiang","year":"2018","unstructured":"Jiang X, Shen W, Xu X, Shen X, Li Y, He Q. Immunosuppressive therapy for steroid-resistant nephrotic syndrome: a Bayesian network meta-analysis of randomized controlled studies. Clin Exp Nephrol. 2018;22(3):562\u20139.","journal-title":"Clin Exp Nephrol"},{"key":"1575_CR24","first-page":"Cd003594","volume":"10","author":"EM Hodson","year":"2016","unstructured":"Hodson EM, Wong SC, Willis NS, Craig JC. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane database of Syst Rev. 2016;10:Cd003594.","journal-title":"Cochrane database of Syst Rev"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1575-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-019-1575-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1575-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,2]],"date-time":"2022-10-02T12:35:41Z","timestamp":1664714141000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-019-1575-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,23]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1575"],"URL":"https:\/\/doi.org\/10.1186\/s12882-019-1575-8","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,23]]},"assertion":[{"value":"9 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N\/A.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"384"}}